This is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia.
Patients voluntarily sign the informed consent form;
Age between 18 and 65 years, regardless of gender;
(1) Relapse: Relapse within 12 months after first remission following standard treatment;
No remission after ≥6 weeks of induction therapy or two courses of induction therapy;
Active central nervous system (CNS) leukemia (patients with CNS disease symptoms must undergo lumbar puncture to exclude CNS leukemia);
Isolated extramedullary relapse;
Prior CAR-T therapy or other genetically modified cell therapy within 6 months before screening;
Pre-treatment chemotherapy as specified in the protocol;
Single group
STR-P004
DrugThis study enrolls adult patients with B-cell acute lymphoblastic leukemia (B-ALL). Enrolled patients receive STR-P004 at the corresponding dose via intravenous infusion, administered four times
Safety and tolerability endpoints
Dose-limiting toxicity (DLT), all adverse events (AEs)/serious adverse events (SAEs), and other safety evaluation indicators
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
